An overview of metformin in the treatment of type 2 diabetes mellitus

American Journal of Medicine

Volumn 102, Issue 1, 1997, Pages 99-110

  Davidson, Mayer B ^a,c   Peters, Anne L ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GLUCOSE UTILIZATION; HUMAN; INSULIN BINDING; INSULIN RELEASE; INSULIN TREATMENT; LACTIC ACIDOSIS; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; METFORMIN; SULFONYLUREA COMPOUNDS;

EID: 0031053808     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00353-1     Document Type: Review

References (87)

1. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet. 1994;343:95-100.
2. Yki-Järvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet. 1994;343:91-95.
3. DeFronzo RA. The triumvirate: β-cell, muscle, liver. Diabetes. 1988;37:667-687.
4. Hother-Nielsen O, Beck-Nielsen H. Basal glucose metabolism in type 2 diabetes. A critical review. Diabetes Metab. 1991;17:136-145.
5. Warram JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;13:909-915.
6. Bennett PH. Epidemiology of diabetes mellitus. In: Rifkin H, Porte D, eds.Ellenberg and Rifkin's Diabetes Mellitus. New York: Elsevier;1990:363-370.
7. Barnett AM, Eff C, Leslie RDG, Pyke DA. Diabetes in identical twins: a study of 200 pairs. Diabetologia. 1981;20:87-93.
8. Hales CN, Barker DJP: Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 1992;35:595-601.
9. Campbell IW. Management of type 2 diabetes mellitus with special reference to metformin therapy. Diabetes Metab. 1991;17 (Suppl.):191-196.
10. Galloway JA. Treatment of NIDDM with insulin agonists or substitutes. Diabetes Care. 1990;13:1209.
11. Watkins PJ. Guidelines for good practice in the diagnosis and treatment of non-insulin-dependent diabetes mellitus. J R Coll Physicians. 1993;27:259-266.
12. Lefèbvre PJ, Scheen AJ. Management of non-insulin-dependent diabetes mellitus. Drugs. 1992;44 (Suppl. 3):29-38.
13. Jackson RA, Hawa MI, Jaspan JB, Sim BM. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes. 1987;36:632-640.
14. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care. 1990;13:696-704.
15. Hermann LS, Melander A. Biguanides: Basic aspects and clinical use. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. New York: John Wiley and Sons 1992:77-95.
16. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br Med J. 1995;310:83-88.
17. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15:755-772.
18. Hother-Nielsen O, Schmitz O, Andersen PH, et al. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol Copenh. 1992;120:257-265.
19. Marena S, Tagliaferro V, Montegrosso G, et al. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabetes Metab. 1994;20:15-19,1994.
20. McIntyre HD, Ma A, Bird DM, et al. Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Aust NZ J Med. 1991;21:714-719.
21. Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabetes Metab. 1986;12:346-350.
22. Widen EIM, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes. 1992;41:354-358.
23. Johnson AB, Webster JM, Sum CF, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type-II diabetic patients. Metabolism. 1993;42:1217-1222.
24. Riccio A, Del Prato S, Vigili de Kreutzenberg S, Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin. Diabetes Metab. 1991;17:180-184.
25. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 73:1294-1301.
26. Hundal HS, Ramlal T, Reyes R, et al. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinol. 1992;131:1165-1173.
27. Klip A, Guma A, Ramlal T, et al. Stimulation of hexose transport by metformin in L6 muscle cells in culture. Endocrinol. 1992;130:2535-2544.
28. Kozka IJ, Holman GD. Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes. 1993;42:1159-1165.
29. Matthaei S, Greten H. Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane. Diabetes Metab. 1991;17 (Suppl. 1):150-158.
30. Matthaei S, Hamann A, Klein HH, Benecke H. Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes. Diabetes. 1991;40:850-857.
31. Matthaei S, Hamann A, Klein HH, Benecke H. Evidence that metformin increases insulin-stimulated glucose transport by potentiating insulin-induced translocation of glucose transporters from an intracellular pool to the cell surface in rat adipocytes. Horm Metab Res. 1992;26 (Suppl.):34-41.
32. Matthaei S, Reibold JP, Hamann A, et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinol. 1993;133:304-311.
33. Sarabia V, Lam L, Burdett E, et al. Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J Clin Invest. 1992;90:1386-1395.
34. Galuska D, Zierath J, Thorne A, et al. Metformin increases insulin-stimulated glucose transport in insulin-resistant human skeletal muscle. Diabetes Metab. 1987;17 (Suppl. 1):159-163.
35. Hamann A, Benecke H, Greten H, Matthaei S, Metformin increases glucose transporter protein and gene expression in human fibroblasts. Biochem Biophys Res Commun. 1993;196:382-387.
36. Nosadini R, Avogaro A, Trevisan R, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care. 1987;10:62-67.
37. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of action of metformin in NIDDM. Diabetes. 1994;43:920-928.
38. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. NEJM. 1995;333:550-554.
39. Gregorio F, Ambrosi F, Marchetti P, et al. Low dose metformin in the treatment of type II non-insulin-dependent diabetes:clinical and metabolic evaluations. Acta Diabetol Lat. 1990;27:139-155.
40. Landin K, Tengborn L, Smith U. Metformin and metoprolol CR treatment in non-obese men. J Intern Med. 1994;235:335-341.
41. Pedersen O, Nielsen O, Bak J, et al.The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes. Diabetic Med. 1989;6:249-256.
42. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol. 1993;44:107-112.
43. Nagi DK, Mohamed Ali V, Yudkin JS. Effects of metformin on intact and des 31, 32 proinsulin in subjects with non-insulin-dependent diabetes. Diabetic Med. 1994;11 (Suppl. 1):25-26.
44. Giugliano D, de Rosa N, di Maro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993;16:1387-1390.
45. Rudnichi A, Fontbonne A, Safar M, et al. The effect of metformin on the metabolic anomalies associated with android type body fat distribution. Results of the BIGPRO trial. (Abstract). Diabetes. 1994;43 (Suppl.):150A.
46. Rizkalla SW, Elgrably F, Tchobroutsky G, Slama G. Effects of metformin treatment on erythrocyte insulin binding in normal weight subjects, in obese non diabetic subjects, in type 1 and type 2 diabetic patients. Diabetes Metab. 1986;12:219-224.
47. Trischitta V, Gullo D, Pezzino V, Vigneri R. Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II diabetic patients. J Clin Endocrinol Metab. 1983;57:713-718.
48. Prager R, Schernthaner G. Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance following metformin treatment. Results of a double-blind cross-over study in type II diabetics. Diabetes. 1983;32:1083-1086.
49. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12:235-246.
50. Glucophage Prescribing Information. Princeton New Jersey: Bristol Meyers Squibb, 1995.
51. Lucis OJ. The status of metformin in Canada. Can Med Assoc J. 1983;128:24-26.
52. Vigneri R, Goldfine RD. Role of metformin in the treatment of diabetes mellitus. Diabetes Care. 1987;10:118-122.
53. Scheen AJ, Salvatore AC, Alves de Magalhaes AC, Lefebvre PJ. Reduction of the acute bioavailability of metformin by the alpha glucosidase inhibitor acarbose in normal man. (Abstract). Eur J Clin Invest. 1994;24 (Suppl. 3):50-54.
54. Josse RG. Acarbose for the treatment of Type II diabetes: the results of a Canadian multi-centre trial. Diabetes Res Clin Pract. 1995;28 (Suppl.):S167-S172.
55. Somogyi, A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987;23:545-551.
56. Arafat T, Kaddoumi A, Shami M, Yassin M. Pharmacokinetics and pharmacodynamics of two oral formulations of metformin hydrochloride. Adv Ther. 1994;11;21-33.
57. Brookes LG, Sambol NC, Lin ET, et al. Effect of dosage for dose and food on the pharmacokinetics of metformin. (Abstract). Pharm Res. 1991;8 (Suppl.):320.
58. Pentikäinen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16:195-202.
59. Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care. 1991;14:342-344.
60. DeFronzo RA, Goodman A, Metformin Investigator Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. NEJM. 1995;333:541-549.
61. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care. 16:621-629.
62. Campbell IW, Duncan CD, Patton NW, et al. The effect of metformin on glycaemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus. Diabetic Med. 1987;4:337-341.
63. Campbell IW, Menzies DG, Chalmers J et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabetes Metab. 1994;21:394-400.
64. Clarke BF, Duncan LJ. Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetics. Lancet 1968;1:123-126.
65. Hermann LS, Kjellstrom T, Schersten B, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994;17:1100-1109.
66. Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of non-insulin-dependent diabetes mellitus. Diabetes Metab. 1991;17 (Suppl. 1):209-212.
67. Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese maturity-onset diabetics uncontrolled by diet. Br Med J. 1977;2: 1576-1578.
68. Wu M-S, Johnston P, Sheu WH-H, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care. 1990;13:1-8.
69. Rains SGH, Wilson GA, Richmond W, Elkeles RS. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabetic Med. 1988;5:653-658.
70. Rains SGH, Wilson GA, Richmond W, Elkeles RS. The reduction in low density lipoprotein cholesterol by metformin is maintained with long term therapy. J R Soc Med. 1989;82:93-94.
71. Schneider J, Erren T, Zofel P, Kaffarnik H. Metformin-induced changes in serum lipids, lipoproteins and apoproteins in non-insulin-dependent diabetes mellitus. Atherosclerosis. 1990;82:97-103.
72. Mendoza SG, Faieta A, Carrasco H, Hamer T, Clueck CJ. Metformin lowers blood pressure, insulin resistance, triglycerides, and endogenous estradiol in hypertensive men. Clin Res. 1994;42:338A.
73. Landin K, Tengborn I, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Int Med. 1991;229:181-187.
74. Landin-Wilhelmsen K. Metformin and blood pressure. J Clin Pharm Ther. 1992;17:75-79.
75. Haupt E, Knick B, Koschinsky T, et al. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab. 1991;17 (Suppl. 1):224-231.
76. Trischitta V, Italia S, Mazzarino S, et al. Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care. 1992;15:539-542.
77. Groop L, Widen E: Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy? Diabetes Metab. 1991;17 (Suppl. 1):218-223.
78. Klein W. Sulfonylurea-metformin combination versus sulfonylurea-insulin combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients. Diabete Metab. 17 (Suppl. 1):235-240.
79. Shlossberg AH. Treating non-insulin-dependent diabetes. Canadian Family Physician. 1993;39:119-126.
80. Lebovitz HE. Oral hypoglycemic agents. In: Rifkin H, Porte D Jr., eds. Diabetes Mellitus Theory and Practice. New York: Elsevier, 1990:554-574.
81. Reaven GM, Chen YDI, Coulston AM, et al. Insulin secretion and action in non-insulin-dependent diabetes mellitus: is insulin resistance secondary to hyperinsulinaemia? Am J Med. 1983;75 (Suppl.5B):85-93.
82. Leblanc H, Marre M, Billault B, Passa P. Interet de l'association infusion sous-cutanee d'insuline et metformine chez 10 diabetiques insulino-necessitants obeses. Diabetes Metab. 1987;13:613-617.
83. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 1989;12:203-208.
84. Bergman U, Boman G, Bengt-Erik W. Epidemiology of adverse drug reactions to phenformin and metformin. Br Med J. 1978;2:464-466.
85. Tomkin GH. Malabsorption of vitamin B12 in diabetic patients treated with phenformin: a comparison with metformin. Br Med J. 1973;3:673-675.
86. Bailey CJ, Nattrass M. Treatment-metformin. Bailliere's Clinical Endocrinology & Metabolism. 1988;2:455-476.
87. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Safety. 1994;11:223-241.